Pregled bibliografske jedinice broj: 166472
Clinical significance of uropathogen Mycoplasma - preliminary results
Clinical significance of uropathogen Mycoplasma - preliminary results // 4th Croatian Congress on Infectious Diseases with international participation / Jeren, Tatjana (ur.).
Zagreb, 2004. (predavanje, nije recenziran, sažetak, znanstveni)
CROSBI ID: 166472 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Clinical significance of uropathogen Mycoplasma - preliminary results
Autori
Mareković, I ; Škerk, V ; Tambić-Andrašević, A
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
4th Croatian Congress on Infectious Diseases with international participation
/ Jeren, Tatjana - Zagreb, 2004
Skup
4th Croatian Congress on Infectious Diseases with international participation
Mjesto i datum
Opatija, Hrvatska, 02.10.2004. - 06.10.2004
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Nije recenziran
Ključne riječi
Clinical significance; uropathogen Mycoplasma
Sažetak
Ureaplasma urealyticum and Mycoplasma hominis are part of normal flora in urogenital tract of certain percent of population. Thus isolation of these microorganisms itself is not a clear evidence of urogenital infection and its clinical significance presents a difficult problem. Presented will be preliminary results of scientific project “ Clinical significance of U. urealyticum and M. hominis “ which is momentarily conducted in University Hospital for Infectious Diseases “ Dr Fran Mihaljević” – Zagreb. The aim of this prospective study was to determine the prevalence of U. urealyticum and M. hominis, to compare semiquantitative findings in urethral and endocervical swabs with presence of clinical symptoms of urethral syndrome and cervicitis, to determine susceptibility of U.urealyticum and M. hominis to erythromycin, doxycycline, tetracycline, ofloxacin and clindamycin and to monitor the outcome of antimicrobial treatment. Detection and quantification of U. urealyticum and M. hominis in clinical specimens was performed by MYOPLASMA DUO test (Bio-Rad Laboratories) and antimicrobial susceptibility testing by S.I.R. MYCOPLASMA test (Bio-Rad Laboratories). The prevalence of U. urealyticum and M. hominis regarding patients’ age and gender was examined on total of 448 patients. In 122 female patients available for monitoring number of mycoplasmas present in urethral and endocervical swabs were not significantly different between patients with colonization and patients with urethral syndrome and cervicitis. Susceptibility testing performed on 31 M. hominis strains has shown more than 90 % of susceptible strains on all antimicrobial agents tested (except 100 % resistance to erythromycin as a result of inherited resistance). The highest rate of resistance in 324 U. urealyticum strains was determined to clindamycin to which 205 strains (63, 3 %) were resistant. Both, U.urealyticum and M. hominis has shown high rates of susceptibility to doxycycline (97, 5 % and 96, 8 % respectively). In 40 patients with urethral syndrome and cervicitis clinical cure was achieved in 30 patients (75, 0 %) and eradication in 33 patients (82, 5 %). The number of mycoplasmas present in urethral and endocervical swabs as only diagnostic criterion is not adequate to differentiate colonization from urethral syndrome and cervicitis. The criteria for their differentiation should be broadened. Except the number of mycoplasma present in specimen these criteria must also include the presence of clinical symptoms and absence of other possible causing pathogens. High rate of U. urealyticum and M. hominis susceptible strains to antimicrobial agents tested, especially doxycycline, in patients with urethral syndrome and cervicitis was concordant with high rate of clinical cure and eradication.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti